Efficacy of Antiresorptive Treatment in Osteoporotic Older Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

J Nutr Health Aging. 2022;26(8):778-785. doi: 10.1007/s12603-022-1825-5.

Abstract

Objectives: To investigate concerns surrounding the benefits of antiresorptive drugs in older adults, a systematic review was carried out to evaluate the efficacy of these treatments in the prevention of osteoporotic hip fractures in older adults.

Design: a systematic review and meta-analysis of randomized clinical trials.

Setting and participants: older adults ≥65 years with osteoporosis, with or without a previous fragility fracture. Studies with cancer-related and corticosteroid-induced osteoporosis, participants <65 years and no reported hip fracture were not included.

Methods: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, ISI Web of Science and Scopus databases were searched. The primary outcome was hip fracture, and subgroup analysis (≥75 years, with different drug types and secondary prevention) and sensitivity analysis was carried out using a GRADE evaluation. Secondary outcomes were any type of fractures, vertebral fracture, bone markers and adverse events. The risk of bias was assessment with the Cochrane risk of bias tool.

Results: A total of 12 randomised controlled trials (RCTs) qualified for this meta-analysis, with 36,196 participants. Antiresorptive drugs have a statistically significant effect on the prevention of hip fracture (RR=0.70; 95%CI 0.60 to 0.81), but with a moderate GRADE quality of evidence and a high number needed to treat (NNT) of 186. For other outcomes, there is a statistically significant effect, but with a low to moderate quality of evidence. Antiresorptives showed no reduction in the risk of hip fracture in people ≥75 years. The results for different drug types, secondary prevention and sensitivity analysis are similar to the main analyses and have the same concerns.

Conclusions: Antiresorptive drugs have a statistically significant effect on preventing hip fracture but with a moderate quality (unclear/high risk of bias) and high NNT (186). This small benefit disappears in those ≥75 years, but increases in secondary prevention. More RCTs in very old osteoporotic adults are needed.

Keywords: Age-related changes; bone; drug-related; hip fracture; osteoporosis.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Aged
  • Bone Density Conservation Agents* / adverse effects
  • Hip Fractures* / drug therapy
  • Hip Fractures* / etiology
  • Hip Fractures* / prevention & control
  • Humans
  • Osteoporosis* / complications
  • Osteoporosis* / drug therapy
  • Osteoporosis* / prevention & control
  • Osteoporotic Fractures* / prevention & control
  • Randomized Controlled Trials as Topic
  • Spinal Fractures* / drug therapy

Substances

  • Bone Density Conservation Agents